While immunotherapy is the preferred front-line treatment method for patients with hepatocellular carcinoma (HCC), only a small number of patients achieve complete response, which results in a lack of radiographic apparent disease. It is not well known if clinical or molecular features may define HCCs sensitive to immunotherapies. To determine the long-term survival outcomes and characteristics of patients with advanced HCC who achieve complete response from immunotherapy, a recent post hoc analysis examined patient data from the IMbrave150 trial and a multicenter cohort analysis. ...
Liver
Advertisement
Drs. Finn and Yopp discuss the challenges of defining high-risk patient populations in adjuvant therapy trials for HCC.
Nivolumab plus ipilimumab provided a higher OS and ORR rate, supporting the combination as a potential standard of care.
Dr. Pasche discusses the trial that led to the TheraBionic P1 device's regulatory approval by the FDA.
Dr. Weinberg provided his perspective on the CheckMate 9DW expanded analyses, as well as multiple studies in CRC.
Previous data pointed to the benefit of adjuvant immunotherapy for patients with HCC through the use of CIK cells.
Dr. Lieu details practice-changing studies from ASCO GI 2025, including CheckMate-9DW, CheckMate 8HW, and BREAKWATER.
In EMERALD-1, investigators analyzed the combination of durvalumab plus bevacizumab and TACE versus placebo with TACE.
Additional analyses from the CheckMate 9DW study shed further light on the clinical efficacy and safety of ipi/nivo for uHCC.
The study reinforces the potential of triplet blockade with casdozo, atezo, and bev as a viable approach for managing uHCC.
Dr. Finn previews key abstracts in liver cancer and other hepatobiliary malignancies from ASCO GI 2025.
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.